Global Denys-Drash Syndrome Market, By Diagnosis (Laboratory Tests, Imaging Tests, Kidney Biopsy, Others), Treatment (Renal Replacement Therapy, Kidney Transplantation, Medication, Others), Age of Onset (Childhood, Adolescent, Infancy, Neonatal), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Denys-Drash syndrome (DDS) is characterized by congenital nephropathy, a malignant tumor of the kidney called Wilms tumor, and sexual development problems in affected males. The majority of girls that are impacted have normal genitalia. DDS is a hereditary condition caused by mutations in the WT1 tumor suppressor gene, resulting in renal failure before three and aberrant sexual organ development. Denys-Drash syndrome puts children at a higher risk for a variety of cancer.
Data Bridge Market Research analyses that the Denys-Drash syndrome market was valued at USD 288.6 million in 2021 and is expected to reach USD 459.98 million by 2029, registering a CAGR of 6.00% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Laboratory Tests, Imaging Tests, Kidney Biopsy, Others), Treatment (Renal Replacement Therapy, Kidney Transplantation, Medication, Others), Age of Onset (Childhood, Adolescent, Infancy, Neonatal), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy's Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Lupin (India), Allergan (Ireland)
|
|
Market Opportunities
|
|
Market Definition
Denys-Drash syndrome (DDS) is a syndromic glomerular disease defined by nephropathy manifesting as persistent proteinuria or overt nephrotic syndrome, Wilms tumor, and genitourinary structural abnormalities. Fluid and electrolyte control, hypertension medication, and chemotherapy for Wilms tumor, if present, are all part of medical care. When DDS is diagnosed before Wilms tumor develops, prophylactic removal of the kidneys (nephrectomy) is indicated. Following end-stage renal failure or nephrectomy, renal replacement therapy, such as dialysis or kidney transplantation, is suggested. Because of the increased risk of gonadal cancer, surgical removal of internal reproductive organs (gonadectomy) is indicated. Genetic counselling is strongly advised. Symptomatic and supportive treatment is the only other option.
Denys-Drash Syndrome Market Dynamics
Drivers
- Rising incidences of Denys-Drash syndrome
The surging incidences of Denys-Drash syndrome is a major factor driving the market's growth rate during the forecast period of 2022-2029. Denys-Drash syndrome is a kidney disorder that appears in the first few months of birth. Diffuse glomerulosclerosis is a disorder in which scar tissue grows across the glomeruli, which are the microscopic blood arteries in the kidneys that filter waste from the blood. Denys-Drash syndrome is a disease that frequently leads to renal failure in children.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of Denys-Drash syndrome market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising government initiatives to spread awareness and the sedentary lifestyle of people will result in the expansion of Denys-Drash syndrome market. Along with this, favorable reimbursement policies and surging pediatric populations will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
The market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Denys-Drash syndrome market growth.
Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the Denys-Drash syndrome market growth.
Restraints/Challenges
On the other hand, high cost associated with the available treatment and diagnosis will obstruct the growth rate of the market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the Denys-Drash syndrome market. Additionally, lack of cure and awareness about genetic diseases and unfavourable healthcare policies will restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This Denys-Drash syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Denys-Drash syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Denys-Drash syndrome (DDS) has an unknown prevalence. In the medical literature, over 200 cases have been reported.
Denys-Drash syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Global Denys-Drash Syndrome Market Scope
The Denys-Drash syndrome market is segmented on the basis of diagnosis, treatment, age of onset, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Age of Onset
- Childhood
- Adolescent
- Infancy
- Neonatal
Route of Administration
- Oral
- Parenteral
- Others
Diagnosis
- Laboratory Tests
- Imaging Tests
- Ultrasound
- Others
- Kidney Biopsy
- Others
Treatment
- Renal Replacement Therapy
- Kidney Transplantation
- Medication
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Denys-Drash Syndrome Market Regional Analysis/Insights
The Denys-Drash syndrome market is analysed and market size insights and trends are provided by country, diagnosis, treatment, age of onset, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Denys-Drash syndrome market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the Denys-Drash syndrome market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. Due to the growing prevalence of Denys-Drash syndrome and rising healthcare expenditure, this will further propel the market's growth rate in this region. Additionally, growing presence of major key players will further propel the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Denys-Drash Syndrome Market Share Analysis
The Denys-Drash syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Denys-Drash syndrome market.
Some of the major players operating in the Denys-Drash syndrome market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. Reddy's Laboratories Ltd. (India)
- Gilead Sciences, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- AbbVie Inc. (U.S.)
- Lupin (India)
- Allergan (Ireland)
SKU-